How to Use Retatrutide
Retatrutide is administered as a once-weekly subcutaneous injection, starting at 2 mg and escalating every 4 weeks to a maintenance dose of 4 mg, 9 mg, or 12 mg depending on tolerability and treatment goals, with injections rotated between the abdomen, thighs, buttocks, or upper arms. 1
Dosing Schedule and Escalation
Starting Dose
- Begin with 2 mg subcutaneously once weekly for the first 4 weeks 2, 3, 4
- This lower starting dose significantly reduces gastrointestinal side effects compared to initiating at 4 mg 4, 5
Dose Escalation
Increase by 2-4 mg increments every 4 weeks based on tolerability:
- Week 0-4: 2 mg weekly
- Week 5-8: 4 mg weekly
- Week 9-12: 6-8 mg weekly (if escalating to higher doses)
- Week 13+: Maintenance dose of 4 mg, 9 mg, or 12 mg weekly 2, 3, 4
Target Maintenance Doses
- 4 mg weekly: For patients prioritizing tolerability or with modest weight loss goals (achieves ~12-17% weight reduction) 2, 4
- 9 mg weekly: Balanced efficacy and tolerability (achieves ~17% weight reduction) 2
- 12 mg weekly: Maximum efficacy (achieves ~19-24% weight reduction) 2, 5
Injection Technique
Administration Details
- Self-administered subcutaneous injection using pre-filled pen device 1
- Injection sites: Rotate between abdomen, thighs, buttocks, or upper arms 1
- Timing: Same day each week, any time of day, with or without food 1
Missed Dose Protocol
- If missed, administer within 3 days of scheduled dose, then resume regular weekly schedule 1
- If more than 3 days have elapsed, skip the missed dose and resume at next scheduled time 1
Monitoring Requirements
Baseline Assessment
Before initiating treatment, evaluate:
- Weight and BMI
- HbA1c (if diabetic; target 6.5-10.5% for treatment eligibility) 2, 3
- Fasting glucose and lipid panel
- Blood pressure and heart rate (retatrutide causes dose-dependent heart rate increases that peak at 24 weeks) 5
- Renal and hepatic function
- History of pancreatitis, medullary thyroid carcinoma, or MEN2 syndrome (contraindications)
Ongoing Monitoring
Weeks 0-24 (Escalation Phase):
- Every 4 weeks: Weight, vital signs (especially heart rate), gastrointestinal tolerability
- Week 12: HbA1c (if diabetic), fasting glucose 3, 4
- Assess for hypoglycemia if on concurrent sulfonylureas or insulin (dose reduction may be needed)
Week 24 onwards (Maintenance Phase):
- Every 12 weeks: Weight, HbA1c (if diabetic), lipid panel, vital signs 2, 3
- Monitor for sustained heart rate elevation (typically declines after 24 weeks) 5
Key Safety Monitoring
Gastrointestinal Events:
- Most common adverse events are nausea (14-28%), diarrhea (27-34%), and vomiting 2
- These are dose-dependent, typically mild-to-moderate, and subside over time 2, 4
- Permanent discontinuation due to adverse events occurs in 4-12% of patients (higher with 9-12 mg doses) 2
Cardiovascular:
- Monitor for hypotension (occurs in 1-6% of patients, dose-dependent) 2
- Heart rate increases are transient and peak at 24 weeks 5
Metabolic:
- No severe hypoglycemia reported in clinical trials 3, 4
- Monitor for dysesthesia (occurs in 4-7% of patients) 2
Clinical Pearls and Pitfalls
Optimizing Tolerability
- Always start at 2 mg rather than 4 mg to reduce gastrointestinal side effects by approximately 50% 4, 5
- Slower escalation (2 mg increments every 4 weeks) improves tolerability compared to faster escalation 4
- Gastrointestinal events typically resolve with continued treatment 2, 4
Patient Selection
- Obesity with T2D: All doses (4-12 mg) show robust efficacy for both weight loss and glycemic control 2, 3
- Obesity without T2D: Higher doses (8-12 mg) achieve superior weight reduction (22-24% at 48 weeks) 5
- Consider lower maintenance doses (4 mg) in patients with significant gastrointestinal intolerance
Concomitant Medications
- Reduce or discontinue sulfonylureas/insulin before starting to minimize hypoglycemia risk 3
- Metformin can be continued safely 4
- Monitor patients on oral estrogen, glucocorticoids, or thyroid hormone for potential dose adjustments (based on general incretin principles)